Pain Drug Developer Latigo Biotherapeutics Plans IPO
Latigo Biotherapeutics, a pain drug developer focused on non-opioid treatments targeting sodium ion channels, plans to go public and list on the Nasdaq under the ticker symbol 'LTGO'. The company has raised $322 million since inception but reported significant financial losses. It joins other biotech firms entering the market for innovative acute pain therapies.